Virtual Event | October 3, 2022

What's Driving The Cell & Gene Therapy Outsourcing Capacity Cycle?

Source: Cytiva

The feared, then realized capacity shortage in the cell & gene outsourcing space appears to be abating. But the market – and economy – remain in flux. We could be heading for overcapacity for some services, but remain constricted in others.

In October 2022, Outsourced Pharma Live's panelists discussed the identified macro and micro trends impacting deal-making at CDMOs. Exclusive data from BioPlan Associates was also presented. Learn what to be on the lookout for as well as how to prepare and take advantage of (another) "life cycle" in our industry – this time in the cell & gene therapy space.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma